根据Hims & Hers Health Inc.提交给美国证券交易委员会(SEC)的文件,目前尚不清楚美国食品和药物监督管理局(FDA)、美国卫生与公众服务部(HHS)或司法部(DOJ)可能对复合GLP-1产品的营销采取何种监管行动。
根据Hims & Hers Health Inc.提交给美国证券交易委员会(SEC)的文件,目前尚不清楚美国食品和药物监督管理局(FDA)、美国卫生与公众服务部(HHS)或司法部(DOJ)可能对复合GLP-1产品的营销采取何种监管行动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.